316 related articles for article (PubMed ID: 30793413)
1. CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
Fuchs C; Medici G; Trazzi S; Gennaccaro L; Galvani G; Berteotti C; Ren E; Loi M; Ciani E
Brain Pathol; 2019 Sep; 29(5):658-674. PubMed ID: 30793413
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
[TBL] [Abstract][Full Text] [Related]
3. The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
Trovò L; Fuchs C; De Rosa R; Barbiero I; Tramarin M; Ciani E; Rusconi L; Kilstrup-Nielsen C
Neurobiol Dis; 2020 May; 138():104791. PubMed ID: 32032735
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
Katayama S; Sueyoshi N; Inazu T; Kameshita I
Neural Plast; 2020; 2020():6970190. PubMed ID: 32587608
[TBL] [Abstract][Full Text] [Related]
5. Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
Loi M; Trazzi S; Fuchs C; Galvani G; Medici G; Gennaccaro L; Tassinari M; Ciani E
Mol Neurobiol; 2020 May; 57(5):2244-2262. PubMed ID: 32002787
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
[TBL] [Abstract][Full Text] [Related]
7. A GABA
Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
[TBL] [Abstract][Full Text] [Related]
8. CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder.
Trazzi S; De Franceschi M; Fuchs C; Bastianini S; Viggiano R; Lupori L; Mazziotti R; Medici G; Lo Martire V; Ren E; Rimondini R; Zoccoli G; Bartesaghi R; Pizzorusso T; Ciani E
Hum Mol Genet; 2018 May; 27(9):1572-1592. PubMed ID: 29474534
[TBL] [Abstract][Full Text] [Related]
9. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
[TBL] [Abstract][Full Text] [Related]
10. CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling.
Zhu ZA; Li YY; Xu J; Xue H; Feng X; Zhu YC; Xiong ZQ
Cell Rep; 2023 Oct; 42(10):113202. PubMed ID: 37777961
[TBL] [Abstract][Full Text] [Related]
11. mGluR5 PAMs rescue cortical and behavioural defects in a mouse model of CDKL5 deficiency disorder.
Gurgone A; Pizzo R; Raspanti A; Chiantia G; Devi S; Comai D; Morello N; Pilotto F; Gnavi S; Lupori L; Mazziotti R; Sagona G; Putignano E; Nocentini A; Supuran CT; Marcantoni A; Pizzorusso T; Giustetto M
Neuropsychopharmacology; 2023 May; 48(6):877-886. PubMed ID: 35945276
[TBL] [Abstract][Full Text] [Related]
12. In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
Carli S; Chaabane L; Butti C; De Palma C; Aimar P; Salio C; Vignoli A; Giustetto M; Landsberger N; Frasca A
J Neurochem; 2021 May; 157(4):1253-1269. PubMed ID: 33448385
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a GSK-3β/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of
Loi M; Gennaccaro L; Fuchs C; Trazzi S; Medici G; Galvani G; Mottolese N; Tassinari M; Giorgini RR; Milelli A; Ciani E
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073043
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
Van Bergen NJ; Massey S; Stait T; Ellery M; Reljić B; Formosa LE; Quigley A; Dottori M; Thorburn D; Stroud DA; Christodoulou J
Neurobiol Dis; 2021 Jul; 155():105370. PubMed ID: 33905871
[TBL] [Abstract][Full Text] [Related]
15. Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder.
Vigli D; Rusconi L; Valenti D; La Montanara P; Cosentino L; Lacivita E; Leopoldo M; Amendola E; Gross C; Landsberger N; Laviola G; Kilstrup-Nielsen C; Vacca RA; De Filippis B
Neuropharmacology; 2019 Jan; 144():104-114. PubMed ID: 30326240
[TBL] [Abstract][Full Text] [Related]
16. Treatment with FRAX486 rescues neurobehavioral and metabolic alterations in a female mouse model of CDKL5 deficiency disorder.
Fuchs C; Cosentino L; Urbinati C; Talamo MC; Medici G; Quattrini MC; Mottolese N; Pietraforte D; Fuso A; Ciani E; De Filippis B
CNS Neurosci Ther; 2022 Nov; 28(11):1718-1732. PubMed ID: 35932179
[TBL] [Abstract][Full Text] [Related]
17. Enhanced hippocampal LTP but normal NMDA receptor and AMPA receptor function in a rat model of CDKL5 deficiency disorder.
Simões de Oliveira L; O'Leary HE; Nawaz S; Loureiro R; Davenport EC; Baxter P; Louros SR; Dando O; Perkins E; Peltier J; Trost M; Osterweil EK; Hardingham GE; Cousin MA; Chattarji S; Booker SA; Benke TA; Wyllie DJA; Kind PC
Mol Autism; 2024 Jun; 15(1):28. PubMed ID: 38877552
[TBL] [Abstract][Full Text] [Related]
18. Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder.
Tassinari M; Uguagliati B; Trazzi S; Cerchier CB; Cavina OV; Mottolese N; Loi M; Candini G; Medici G; Ciani E
Neurobiol Dis; 2023 Jun; 182():106146. PubMed ID: 37164289
[TBL] [Abstract][Full Text] [Related]
19. Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder.
Tassinari M; Mottolese N; Galvani G; Ferrara D; Gennaccaro L; Loi M; Medici G; Candini G; Rimondini R; Ciani E; Trazzi S
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955854
[TBL] [Abstract][Full Text] [Related]
20. Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
Fuchs C; Gennaccaro L; Trazzi S; Bastianini S; Bettini S; Lo Martire V; Ren E; Medici G; Zoccoli G; Rimondini R; Ciani E
Neural Plast; 2018; 2018():9726950. PubMed ID: 29977282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
